


## Interim Results

14 December 2015

### Key Statistics

<b>Code</b>	: OPTI
<b>Listing</b>	: AIM
<b>Sector</b>	: Biotechnology
<b>Market Cap</b>	: £54.1m
<b>Share in issue</b>	: 74.23m
<b>Current Price</b>	: 73p
<b>12 mnth High/Low</b>	: 97p/14.62p

### Stock Performance



Source: Fidessa

### Financials (y/e Dec)

Estimated cash balance: £3.7m

Source: 7 December 2015 RNS

### Company description

OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome – the collective genome of the microbes in the body – to prevent and manage human disease. OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen® and OptiBiotic® platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases.

### HYBRIDAN LLP

20 Ironmonger Lane, London, EC2V 8EP

Website: [www.hybridan.com](http://www.hybridan.com)

Derren Nathan

Tel: 020 3764 2344

Email: [derren.nathan@hybridan.com](mailto:derren.nathan@hybridan.com)

## Taking the human microbiome into new territory

The company developing products to modulate the human microbiome to prevent, manage, and treat human disease has last week announced a £1.5m placing at 75p which will help to drive development and commercialisation in its existing programmes but also to pursue opportunities in new application areas. As part of the placing directors of the company subscribed for £110k worth of shares.

Having raised £3.3m at the IPO in August 2014, OptiBiotix has exceeded its promises whilst keeping a tight control on cash burn and net cash is currently estimated to be circa £3.7m.

Part of the placing proceeds will be used to bring more scientific development capability in-house through the recruitment of further scientists, a move which is expected to create additional opportunities with existing and prospective partners.

The company will be turning its attention to further multi-billion dollar markets including **diabetes, bone health** and a number of sub sectors of **skin health** which could be an equal, if not larger opportunity than the currently targeted metabolic and cardiovascular markets. We understand that in terms of initial research and scientific understanding the company has already made progress in the above areas.

We have factored in recent progress plus the new product areas into our valuation model applying appropriately conservative risk weightings generating an **indicative valuation of 95.4p**. Of course the ultimate driver of the company's value will be the monetary value of revenues and milestone payments derived from product sales and partnership agreements, and it is now up to OptiBiotix to deliver income from both routes.

Since the August 2014 IPO, OptiBiotix has delivered six new patent filings, five new microbial strain deposits, and four commercial deals. The company's strategic focus on product development through its proprietary proven platforms, whilst seeking to partner with company's who can provide infrastructure and market access, allows it to explore multiple product opportunities for relatively little capital outlay.

This combined with a strong balance sheet gives OptiBiotix multiple opportunities to reach profitability without further recourse to the equity markets.

*For analyst certification and other important disclosures, refer to the Disclosure Section*

OptiBiotix's achievements to date have validated its technology platforms, and set a precedent that microbial strains that have an effect on human health can be identified and have first human efficacy studies completed within a period of approximately eighteen months for a total development cost of under £0.5m.

The company's work on oligosaccharides will be crucial to future product development, with these novel sugars able to modulate or promote the growth of targeted microbes in humans or industrial processes. This is the platform cornerstoning the development agreement announced last month with Italy's Centro Sperimentale Del Latte (CSL) which researches, develops, manufactures and distributes probiotics, starter cultures, moulds and yeasts for the pharmaceutical, nutraceutical, dairy, food and agricultural sectors all over the world.

However perhaps the most obvious route to take is the development of sweet healthy sugars. The company is therefore creating a dedicated sub platform, SweetBiotix so that it puts more resources into creating zero calorie substitutes for sucrose and fructose with commercially attractive textures, sweetness levels and health benefits. It is likely that the products will also be looking to target satiation (the feeling of fullness) and calorific absorption.

We have reviewed our valuation model to include the new development areas and on existing programmes have adjusted our risk weighting to reflect the progress made.

**Existing products:** For the Cholesterol product we have reduced our risk discount of commercialisation to 45% reflecting the progression from human studies to pilot manufacture and also the unexpected addition of hypertension as a health benefit of this product as underlined by the recent patent filing. There is already an option agreement in place with a multinational consumer goods company to enter into a definitive agreement now that the trial is complete.

SweetBiotix or novel sugars we have leave unchanged at 75%. Whilst a development agreement is in place with CSL there is still much work to do in terms of strain selection, testing and formulation but we expect rapid progress to be made.

Weight management we have reduced to 55% and expect to be able to reduce this further as we receive updates on the Nizo JV and other commercial applications of this well understood technology.

To OptiBiotix's platforms we have applied lowered our risk discount to 45% as we believe that the product development and third party collaborations announced to date validates both the OptiBiotic and OptiScreen platforms.

**New products:** The newest product areas that OptiBiotix has disclosed it is developing are SkinCare under its newly formed SkinBiotix platform, and a pre-diabetic supplement which is seeking to help borderline diabetics improve glycemic regulation and avoid developing type II diabetes.

OptiBiotix has already laid the basic scientific foundations for these product areas and now needs to apply its platform technologies to progress them towards human studies. Some of these areas, which we understand are likely to be classified as medical devices, will have higher regulatory hurdles than the company's existing products. If they edge towards the 'medicine' category this will be even higher although we understand this is not the current plan. We have applied the upmost conservatism in terms of risk discount to each of the new development areas at 95%. In terms of the unrisks valuations we use as a starting point, again we take a low 1% share of the relevant market/sub market size or comparator product and applied a 1x multiple. For cosmetic skin care we have taken 2014 levels of Botox Sales (\$2.2bn per Allergan 2014 annual report). For wound care we have not taken the estimated size of the entire wound care market but rather anti-infective wound dressings market (\$7.5bn per Transparency Market Research). For the diabetes treatment we have looked at the estimated size of the diabetic – centric supplements market (over \$1bn per Nutrition Business Journal). For Eczema, Psoriasis and HCAI we have looked at the relevant market size for these therapeutic areas which are \$3.8bn (by 2018 per GlobalData 2012 report), \$6.6bn (in 2013 per PharmaTimes Digital) and \$3.1bn (Transparency Market Research) respectively.

As the company progresses its product development and path to commercialisation on its products, we see further scope to reduce our risk discount and increase the potential market share that the company might attain, leaving scope for upside many multiples of the current share price. The company has done a great job at validating its platforms, advancing its existing portfolio through to commercial deals and scientific. The onus will be now to repeat this in new product areas, but most importantly to start to crystallise some of the value accrued and yet to be generated through the generation of revenues and milestone payment from its partners. This will solidify our investment case and remove some of the speculative nature of our current valuation parameters. As it stands our model suggests an indicative risked valuation of 95.4p some 30.6% above the current share price.

OptiBiotix sum of the parts valuation	Unrisked value £m	Risk weighting	Risked value	
Cholesterol	58.8	45%	32.4	<i>Benecol</i>
SweetBiotix	27.5	75%	6.9	<i>Stevia</i>
Weight Management	20.7	55%	9.3	<i>Herballife</i>
Platform	43.3	45%	23.8	<i>Nestle</i>
Skinbiotics:				
<i>Health Care Acquired Infections</i>	<i>19.4</i>	<i>95%</i>	<i>1.0</i>	<i>HCAI market size</i>
<i>Eczema</i>	<i>23.8</i>	<i>95%</i>	<i>1.2</i>	<i>Eczema therapeutic market</i>
<i>Psoriasis</i>	<i>41.3</i>	<i>95%</i>	<i>2.1</i>	<i>Psoriasis therapeutic Market</i>
<i>Wound Care</i>	<i>46.9</i>	<i>95%</i>	<i>2.3</i>	<i>Anti-infective dressings</i>
<i>Cosmetic skin care</i>	<i>13.8</i>	<i>95%</i>	<i>0.7</i>	<i>Botox</i>
Pre diabetic supplement	6.3	95%	0.3	<i>Diabetic-centric supplements</i>
Cash			2.3	<i>Estimated 2016 year end</i>
<b>Indicative Valuation</b>			<b>82.2</b>	
Diluted shares in issue			86.2	
<b>Indicative valuation per share (p)</b>			<b>95.4</b>	

Source: Hybridan LLP Valuation model

**Income Statement**

	6 months to 31 May 2015 Unaudited £	6 months to 31 May 2014 Unaudited £	Year to 30 November 2014 Audited £
<b>Continuing operations</b>			
Administrative expenses	(514,431)	(57,643)	(489,015)
<b>Operating loss</b>	(514,431)	(57,643)	(489,015)
<b>Non-Operating Items</b>			
Admission expenses	-	-	(365,038)
Finance income / (costs)	7	-	93
<b>Loss before Income tax</b>	(514,424)	(57,643)	(853,960)
Income tax	-	-	43,254
<b>Loss for the period</b>	(514,424)	(57,643)	(810,706)
<b>Total comprehensive income for the period</b>	(514,424)	(57,643)	(810,706)
Total comprehensive income attributable to the owners of the company	(514,424)	(57,643)	(810,706)
<b>Loss per share</b>			
Basic & Diluted loss per share - pence	0.708p	1.144p	3.03p

Source: OptiBiotix Health PLC Half Year Report

**Cashflow Statement**

	6 months to 31 May 2015 Unaudited £	6 months to 31 May 2014 Unaudited £	Year to 30 November 2014 Audited £
<b>Reconciliation of loss before income tax to cash outflow from operations</b>			
Operating loss	(565,284)	(57,643)	(854,053)
(Increase)/decrease in trade and other Receivables	(23,944)	291,233	296,616
Decrease in trade and other Payables	(24,507)	(201,548)	(212,913)
Share Option expense	127,728	-	63,770
Depreciation	347	-	244
<b>Net cash outflow from operations</b>	<b>(485,660)</b>	<b>32,042</b>	<b>(706,336)</b>
Interest paid	-	-	-
Interest received	7	-	93
<b>Net cash outflow from operating activities</b>	<b>(485,653)</b>	<b>32,042</b>	<b>(706,243)</b>
<b>Cash flows from investing activities</b>			
Purchases of property, plant and equipment	(1,965)	-	(1,099)
Net cash from acquisition of subsidiary	-	-	251,834
<b>Net cash (outflow)/inflow from investing activities</b>	<b>(1,965)</b>	<b>-</b>	<b>250,735</b>
<b>Cash flows from financing activities</b>			
Share issues	87,753	73,029	3,300,068
<b>Net cash inflow from financing activities</b>	<b>87,753</b>	<b>73,029</b>	<b>3,300,068</b>
<b>Taxation</b>	<b>-</b>	<b>-</b>	<b>25,732</b>
<b>Increase/(decrease) in cash and equivalents</b>	<b>(399,865)</b>	<b>105,071</b>	<b>2,870,292</b>
Cash and cash equivalents at beginning of year	2,870,442	150	150
Cash and cash equivalents at end of year	<u>2,470,577</u>	<u>105,221</u>	<u>2,870,442</u>

Source: OptiBiotix Health PLC Half Year Report

**Balance Sheet**

	As at 31 May 2015 Unaudited £	As at 31 May 2014 Unaudited £	As at 30 November 2014 Audited £
<b>ASSETS</b>			
<b>Non-current assets</b>			
Intangibles	2,259,369	-	2,259,369
Property, plant & equipment	2,473	-	855
	<u>2,261,842</u>	<u>-</u>	<u>2,260,224</u>
<b>CURRENT ASSETS</b>			
Trade and other receivables	28,595	10,034	4,651
Current tax asset	94,107	-	43,254
Cash and cash equivalents	2,470,577	105,221	2,870,442
	<u>2,593,279</u>	<u>115,255</u>	<u>2,918,347</u>
<b>TOTAL ASSETS</b>	<u><u>4,855,121</u></u>	<u><u>115,255</u></u>	<u><u>5,178,571</u></u>
<b>EQUITY</b>			
<b>Shareholders' Equity</b>			
Called up share capital	7,100,284	5,742,586	7,078,346
Share premium	3,812,596	1,355,502	3,746,781
Share based payment reserve	218,698	27,200	90,970
Merger relief reserve	1,500,000		1,500,000
Accumulated deficit	(8,281,437)	(7,013,950)	(7,767,013)
<b>Total Equity</b>	<u>4,350,141</u>	<u>111,338</u>	<u>4,649,084</u>
<b>LIABILITIES</b>			
<b>Current liabilities</b>			
Trade and other payables	53,106	3,917	77,613
	<u>53,106</u>	<u>3,917</u>	<u>77,613</u>
<b>Non - current liabilities</b>			
Deferred tax	451,874	-	451,874
	<u>451,874</u>	<u>-</u>	<u>451,874</u>
<b>TOTAL LIABILITITES</b>	<u>504,980</u>	<u>3,917</u>	<u>529,487</u>
<b>TOTAL EQUITY AND LIABILITIES</b>	<u><u>4,855,121</u></u>	<u><u>115,255</u></u>	<u><u>5,178,571</u></u>

Source: OptiBiotix Health PLC Half Year Report

**Research Disclaimer**

This document should not be relied upon as being an impartial or objective assessment of the subject matter and is not deemed to be "independent research" for the purposes of the Financial Conduct Authority rules. As a consequence the research (a) has not been prepared in accordance with legal requirements designed to promote the independence of investment research; and (b) is not subject to any prohibition on dealing ahead of the dissemination of investment research (although Hybridan does impose restrictions on personal account dealing in the run up to publishing research as set out in our Conflicts of Interest Policy).

Hybridan LLP is involved in providing other financial services to **OptiBiotix Health plc** (the "Company") and as a result Hybridan LLP may have responsibilities that conflict with the interests of the persons who receive this document.

This document has been issued by Hybridan LLP for **information purposes only** and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific entity. Hybridan LLP and/or connected persons may, from time to time, effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments. The information contained herein is based on materials and sources that we believe to be reliable, however, Hybridan LLP makes no representation or warranty, either express or implied, in relation to the accuracy, completeness or reliability of the information contained herein. Opinions expressed are our current opinions as of the date appearing on this material only. Any opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. None of Hybridan LLP, its affiliates or employees shall have any liability whatsoever for any indirect or consequential loss or damage arising from any use of this document.

In the UK, this report is directed at and is for distribution only to persons who (i) fall within Article 19(1) (persons who have professional experience in matters relating to investments) or Article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc) of the Financial Services and Markets Act 2000 (Financial Promotions) Order 2005 (as amended) or (ii) are Professional Clients or Eligible Counterparties of Hybridan LLP (all such persons together being referred to as "relevant persons"). This report must not be acted on or relied upon by persons in the UK who are not relevant persons.

Neither this report nor any copy or part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this report comes should inform themselves about, and observe any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of UK or US securities law, or the law of any such other jurisdictions.

Investments in general involve some degree of risk, including the risk of capital loss. The services, securities and investments discussed in this document may not be available to or suitable for all investors. Investors should make their own investment decisions based upon their own financial objectives and financial resources and, if in any doubt, should seek advice from an investment advisor. Past performance is not necessarily a guide to future performance and an investor may not get back the amount originally invested. Where investment is made in currencies other than the investor's base currency, movements in exchange rates will have an effect on the value, either favourable or unfavourable. Levels and bases for taxation may change. When Hybridan LLP comments on AIM or ISDX Markets shares investors should be aware that because the rules for those markets are less demanding than the Official List of the London Stock Exchange the risks are higher. Furthermore, the marketability of these shares is often restricted.

Hybridan LLP and/or its associated companies may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the partners, directors and employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests. Neither the whole nor any part of this material may be duplicated in any form or by any means. Neither should any of this material be redistributed or disclosed to anyone without the prior consent of Hybridan LLP. Hybridan LLP is Authorised and Regulated by the Financial Conduct Authority and is a member of the London Stock Exchange.

Hybridan LLP

20 Ironmonger Lane, London, EC2V 8EP

T +44 (0) 20 3764 2341, F +44 (0) 20 7600 1586

[www.hybridan.com](http://www.hybridan.com)

**Hybridan LLP**  
**Research Disclosures**

Investment analyst certification:

All research is issued under the regulatory oversight of Hybridan LLP. Each Investment Analyst of Hybridan LLP whose name appears as the Author of this Investment Research hereby certifies that the opinions expressed in the Investment Research accurately reflect the Investment Analyst's personal and objective views about any and all of the companies or the Company discussed herein that are within such Investment Analyst's coverage universe.

The Investment Analyst who is responsible for the preparation of this Investment Research is an employee of Hybridan that has been engaged by Hybridan LLP to produce this document.

Investment Research Disclosures:

1. Hybridan LLP may receive compensation for Corporate Finance services from this Company in the next twelve months.
2. Hybridan LLP acts as Corporate Broker for the Company.
3. Hybridan may provide investment banking services to the Company and in that capacity may have received confidential information relevant to the securities mentioned in this research report which is not known to the researcher who has compiled this research report.

Hybridan, its partners, officers or employees or any connected persons may at the time of publication have an interest in the equity of the Company through the holding of warrants, securities, futures, options, derivatives and any other financial instrument of any of the companies referred to in this document. Hybridan at the time of publication currently has no interest of this nature in the Company discussed herein. If exercised this interest would not be required to be notified as it would comprise less than 3% of the Company's issued share capital. Hybridan reserves the right to increase or dispose of this interest and / or the underlying shares resulting from exercise, without further notice. Any disposal or acquisition of warrants or shares will be undertaken under the FCA guidelines regarding Closed Periods and Public Disclosure as required.

Research recommendations:

In line with our conflicts of interest policy Hybridan LLP does not produce recommendations or publish target prices on companies who are corporate clients of Hybridan LLP.